Perfuse Therapeutics
San Francisco, United States (US) · Health and Medical
Do you work at Perfuse Therapeutics?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Perfuse Therapeutics is a Health and Medical company based in San Francisco, United States (US), with 10-20 employees. Perfuse Therapeutics's profile is verified on Enterprise League.
Overview
Perfuse Therapeutics is a US-based clinical-stage biopharmaceutical company located in San Francisco, dedicated to reducing the incidence of blindness. We are pioneering a novel approach to prevent blindness by focusing on improving retinal ischemia through a first-in-class endothelin antagonist.
Our lead therapeutic candidate, PER-001, is a sustained-release intravitreal implant designed to release drug over six months, addressing the underlying pathology in ocular diseases driven by ischemia.
Perfuse’s team combines decades of experience in ocular drug discovery, development, and delivery, supported by a strong intellectual property portfolio and a syndicate of leading venture capital firms. We are committed to advancing innovative therapies to protect and improve the vision of patients with ocular diseases.
Sevgi Gurkan, MD, Founder and CEO, brings extensive experience from Merck and Rutgers, alongside Phillip Lai, MD, Chief Medical Officer, with a proven track record in ophthalmology clinical drug development.
Our lead therapeutic candidate, PER-001, is a sustained-release intravitreal implant designed to release drug over six months, addressing the underlying pathology in ocular diseases driven by ischemia.
Perfuse’s team combines decades of experience in ocular drug discovery, development, and delivery, supported by a strong intellectual property portfolio and a syndicate of leading venture capital firms. We are committed to advancing innovative therapies to protect and improve the vision of patients with ocular diseases.
Sevgi Gurkan, MD, Founder and CEO, brings extensive experience from Merck and Rutgers, alongside Phillip Lai, MD, Chief Medical Officer, with a proven track record in ophthalmology clinical drug development.
Contact Details
info@perfusetherapeutics.com
San Francisco, United States (US), 1700 Owens Street, Suite 540
+1
Company Type
Private Limited Company
Employees
10-20
Categories
Keywords
#biotechnology
#ophthalmology
Companies teams usually look at after Perfuse Therapeutics
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.